Ghiaseddin, A., Dunn-Pirio, A., Peters, K., Vlahovic, G., Herndon, J., Threatt, S., … Desjardins, A. (2014). AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION. Neuro-Oncology, 16(suppl 5), v13–v13. https://doi.org/10.1093/neuonc/nou237.22

Ghiaseddin, A., A. Dunn-Pirio, K. Peters, G. Vlahovic, J. Herndon, S. Threatt, J. Sampson, A. Friedman, H. Friedman, and A. Desjardins. “AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION.” Neuro-Oncology 16, no. suppl 5 (November 1, 2014): v13–v13. https://doi.org/10.1093/neuonc/nou237.22.

Ghiaseddin A, Dunn-Pirio A, Peters K, Vlahovic G, Herndon J, Threatt S, et al. AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION. Neuro-Oncology. 2014 Nov 1;16(suppl 5):v13–v13.

Ghiaseddin, A., et al. “AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION.” Neuro-Oncology, vol. 16, no. suppl 5, Oxford University Press (OUP), Nov. 2014, pp. v13–v13. Crossref, doi:10.1093/neuonc/nou237.22.

Ghiaseddin A, Dunn-Pirio A, Peters K, Vlahovic G, Herndon J, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION. Neuro-Oncology. Oxford University Press (OUP); 2014 Nov 1;16(suppl 5):v13–v13.